We are a clinical-stage biotechnology company developing disruptive first-in-class and best-in-class approaches utilizing autologous regulatory T cells (Tregs), Treg-derived exosome therapeutics and novel biologics to target disease, with an initial focus on neurodegenerative and autoimmune diseases.

Dysfunctional Tregs underlie neurodegenerative and autoimmune diseases, and we are leveraging these seminal discoveries from the laboratory of Stanley Appel M.D., to offer novel therapeutic approaches via our TREG platform. Enabling potent immunosuppressive and neuroprotective functionality and is designed to address the unmet and significant medical needs of patients with amyotrophic lateral sclerosis (ALS), Alzheimer’s, Frontotemporal Dementia (FTD) and other neurodegenerative and autoimmune diseases.

Our CTreg™ platform is the first in the industry to expand, freeze, and re-thaw Tregs, allowing for serial and monthly maintenance infusions while maintaining viability and suppressive function. We have also phenotypically characterized the expanded and rethawed Tregs to allow for quantification of upregulated/reproducible proteins for QC consistency from batch to batch.

Treatment Pipeline Targets Billion Dollar Markets

Our pipeline targets the critical progenitor of the inflammatory pathway-namely Treg dysfunction, regardless of individual downstream pathways. Treg dysfunction is a hallmark in multiple neurodegenerative diseases and autoimmune conditions, providing an opportunity for our therapeutics to be tested in this patient population.

side call out image

“Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of our Treg platform shows great promise in unlocking a new treatment paradigm and will enable us to revolutionize care for patients with devastating neurodegenerative diseases.”

Dr. Stanley Appel

Latest News